Article
Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.
Respiratory research - 21 Jun 2024
Zhang Chenyue, Huo Yanfei, Shang Xiaoling, Zhang Tongming, Tang Ning, Wang Haiyong
Abstract excerpt
BACKGROUND: There is a desperate for the identification of more accurate and efficient biomarkers for ICI responses in patients with SCLC. METHODS: The data of our study was obtained from IMpower133 study. A total of 202 patients with SCLC received the treatment of placebo plus carboplatin plus etoposide (EC) while a total of 201 patients with SCLC received the treatment of atezolizumab plus EC. Overall survival...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.